[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nicolai Jacob Wewer Albrechtsen\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100619891","investigating-the-acute-effects-of-increasing-alanine-exposure-in-healthy-participants-100619891",false,"NCT07350512","Investigating the Acute Effects of Increasing Alanine Exposure in Healthy Participants","Investigating the Effect of Glucagon on Cognitive Function and Cerebral Glucose Metabolism in Humans: A Pilot Study","Inclusion Criteria:\n\n* Capable of understanding the participant information and signing the consent form\n* Between 25 and 70 years of age at the time of screening\n* Body mass index (BMI) ≤ 25 kg\u002Fm2 at the time of screening\n\nExclusion Criteria:\n\n* Enrolment in other research projects that might interfere with the study\n* Diabetes diagnosis (type 1 and 2)\n* Pregnancy or breastfeeding\n* Use of medications which, in the opinion of the investigator, may jeopardise participant's safety or compliance with the protocol\n* Impaired liver function defined as either alanine aminotransferase (ALAT) and\u002For aspartate aminotransferase (ASAT) ≥ 2 times normal values\n* Kidney disease defined as serum creatinine levels ≥ 126 μmol\u002FL for male and ≥ 111 μmol\u002FL for female\n* Inadequately treated blood pressure at screening defined as repeated resting blood pressure outside the range 90-150 mmHg for systolic and 50-100 mmHg for diastolic\n* Active or recent malignant disease\n* Current or history of severe alcohol use or drug\u002Fchemical abuse as per investigator's judgement\n* Any chronic disorders or severe diseases which, in the opinion of the investigator, might jeopardise participant's safety or compliance with the protocol",true,"ALL","25 Years","70 Years",{"count":21,"type":22},15,"ESTIMATED","INTERVENTIONAL",[25],"NA","In this study the investigators will investigate the acute effects of increasing alanine exposure on metabolic parameters in healthy participants.\n\nParticipants will participate in one study day. After initial baseline blood samples, a three-hour intravenous infusion with glucagon will be initiated. The infusion rate will be increased every 30 minutes.",[28,29],"Glucose Metabolism","Glucagon",[31,32,33],"Alanine","glucagon","glucose metabolism","NOT_YET_RECRUITING","2026-01-09",{"date":37,"type":38},"2026-01-20","ACTUAL",{"date":37,"type":22},{"date":41,"type":22},"2027-01-20",{"name":43,"class":44},"Nicolai Jacob Wewer Albrechtsen","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":45},"100565837","development-of-a-non-invasive-method-for-quantifying-cerebral-glucose-metabolism-for-studying-the-effect-of-glucagon-in-humans-100565837","NCT06647368","Development of a Non-invasive Method for Quantifying Cerebral Glucose Metabolism for Studying the Effect of Glucagon in Humans","Investigating the Effect of Glucagon on Cognitive Function and Cerebral Glucose Metabolism in Humans: A Pilot study_A","Inclusion Criteria:\n\n* Capable of understanding the participant information and signing the consent form\n* Between 25 and 70 years of age\n* Body mass index \\\u003C= 25 kg\u002Fm\\^2\n\nExclusion Criteria:\n\n* Enrolment in other research project that might interfere with the study\n* Diabetes diagnosis\n* Pregnancy or breastfeeding\n* Use of medications which, in the opinion of the investigator, may jeopardise participant's safety or compliance with the protocol\n* Diagnosis of psychiatric disorders, dementias, or any other neurological disorders that in the opinion of the investigator precludes compliance with the study protocol, evaluation of the results or represents an unacceptable risk for the participants safety\n* Severe claustrophobia\n* Cardiac problems including any of the following:\n\n  1. Classified as being in New York Heart Association (NYHA) class III or IV\n  2. Angina pectoris (chest pain) within the last 6 months\n  3. Acute myocardial infarction (heart attack) within last 2 years\n* Inadequately treated blood pressure at screening defined as repeated resting blood pressure outside the range 90-150 mmHg for systolic and 50-100 mmHg for diastolic.\n* Active or recent malignant disease\n* Current or history of severe alcohol use or drug\u002Fchemical abuse as per investigator's judgement\n* Any chronic disorders or severe diseases which, in the opinion of the investigator, might jeopardise participant's safety or compliance with the protocol",{"count":54,"type":22},6,[25],"The aim of the study is to develop a non-invasive method for quantifying cerebral glucose metabolism by PET scans in humans. This method will be used in subsequent studies, where the effect of the pancreatic hormone glucagon on cerebral glucose metabolism will be studied.\n\nThe golden standard for quantifying cerebral glucose metabolism by PET scans is based on arterial blood sampling, which complicates research setup. This study will investigate if image derived measurements instead of arterial blood samples can be used to quantify cerebral glucose metabolism.\n\nWe will compare the calculations of cerebral glucose metabolism based on arterial blood samples and image derived measurements and hopefully these will correlate.\n\nHealthy participants will be included, and each participant will participate in one study day, which includes intravenous administration of radioactively labelled glucose (18-FDG), arterial blood sampling and PET scans.",[58],"Cerebral Glucose Metabolism","RECRUITING","2024-10-16",{"date":62,"type":38},"2024-10-17",{"date":64,"type":22},"2024-10-22",{"date":66,"type":22},"2024-12-17",{"name":43,"class":44},""]